Literature DB >> 22286748

siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells.

XiFu Shang1, YaoFei Wang, QiChun Zhao, KeRong Wu, Xu Li, XiaoFeng Ji, Rui He, WenZhi Zhang.   

Abstract

Ezrin, one of the ezrin/radixin/moesin (ERM) protein family which act as membrane organizers and linkers between plasma membrane and cytoskeleton, has attracted much attention as a crucial factor for tumor metastasis. Overexpression of ezrin has been correlated with the metastatic potential of several cancers especially for osteosarcoma. Short interfering RNA (siRNA) downregulate gene expression through an enzyme-mediated process named RNA interference (RNAi). RNAi has rapidly come to be recognized as a powerful tool for the study of gene function and a potential target therapy. In the present study, the human osteosarcoma cell line MG63 was cultured. Three siRNAs targeting ezrin mRNA were designed by the multiple computational methods and then were sythesized. These siRNAs were transfected into osteosarcoma cells. Then the expression of ezrin mRNA and protein in osteosarcoma cells was detected. The cellular proliferation and apoptosis was evaluated. C726–U730, C1653–A1661 and G1749–A1771 were selected to be the suitable target sites through the multiple computational methods because of their ideal secondary structures and hybridization thermodynamics. siRNAs against G1749–A1771 downregulated the expression level of ezrin mRNA and protein, inhibit the cellular proliferation and promoted the cellular apoptosis effectively. There is a significant correlation between the multiple computational methods and the efficacy of the corresponding siRNAs. siRNAs targeting ezrin may have therapeutic potential as inhibitors of osteosarcoma metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286748     DOI: 10.1007/s11010-012-1238-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  56 in total

1.  Predicting oligonucleotide affinity to nucleic acid targets.

Authors:  D H Mathews; M E Burkard; S M Freier; J R Wyatt; D H Turner
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

2.  Keeping the biotechnology of antisense in context.

Authors:  C A Stein
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

3.  Target site selection for an RNA-cleaving catalytic DNA.

Authors:  M J Cairns; T M Hopkins; C Witherington; L Wang; L Q Sun
Journal:  Nat Biotechnol       Date:  1999-05       Impact factor: 54.908

4.  Effects on RNAi of the tight structure, sequence and position of the targeted region.

Authors:  Koichi Yoshinari; Makoto Miyagishi; Kazunari Taira
Journal:  Nucleic Acids Res       Date:  2004-02-03       Impact factor: 16.971

5.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

6.  A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures.

Authors:  O Matveeva; B Felden; S Audlin; R F Gesteland; J F Atkins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

7.  Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor.

Authors:  Torgeir Holen; Mohammed Amarzguioui; Merete T Wiiger; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

8.  Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system.

Authors:  Gary Beale; Andrew J Hollins; Mustapha Benboubetra; Muhammad Sohail; Stephen P Fox; Ibrahim Benter; Saghir Akhtar
Journal:  J Drug Target       Date:  2003-08       Impact factor: 5.121

9.  Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report.

Authors:  Timothy A Damron; William G Ward; Andrew Stewart
Journal:  Clin Orthop Relat Res       Date:  2007-06       Impact factor: 4.176

10.  A structural analysis of in vitro catalytic activities of hammerhead ribozymes.

Authors:  Yu Shao; Susan Wu; Chi Yu Chan; Jessie R Klapper; Erasmus Schneider; Ye Ding
Journal:  BMC Bioinformatics       Date:  2007-11-30       Impact factor: 3.169

View more
  6 in total

1.  Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro.

Authors:  Qing-Yong Chen; Wei Xu; De-Min Jiao; Li-Jun Wu; Jia Song; Jie Yan; Jian-Guo Shi
Journal:  Mol Cell Biochem       Date:  2013-02-22       Impact factor: 3.396

2.  Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.

Authors:  Yisila Mu; Haoshaqiang Zhang; Lixin Che; Kun Li
Journal:  Med Oncol       Date:  2013-12-19       Impact factor: 3.064

3.  The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults.

Authors:  Iwona Lugowska; Ewa Mierzejewska; Malgorzata Lenarcik; Teresa Klepacka; Irena Koch; Elzbieta Michalak; Katarzyna Szamotulska
Journal:  Tumour Biol       Date:  2016-05-20

4.  ß1 integrin binding phosphorylates ezrin at T567 to activate a lipid raft signalsome driving invadopodia activity and invasion.

Authors:  Ester Antelmi; Rosa A Cardone; Maria R Greco; Rosa Rubino; Francesca Di Sole; Nicola A Martino; Valeria Casavola; Marialuisa Carcangiu; Loredana Moro; Stephan J Reshkin
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

Review 5.  A glimpse of the ERM proteins.

Authors:  Godwin A Ponuwei
Journal:  J Biomed Sci       Date:  2016-03-17       Impact factor: 8.410

6.  Influence of ezrin-shRNA in combination with HSP70 on the apoptosis and proliferation of osteosarcoma cells.

Authors:  Qin Yao; Yihua Pei; Huiqin Zhuo; Bozhen Xie
Journal:  Oncol Lett       Date:  2016-09-08       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.